Observations placeholder
Victoza
Identifier
020366
Type of Spiritual Experience
Background
A description of the experience
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Under the brand name Victoza, it is an injectable drug developed for the treatment of type 2 diabetes. In 2015, began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
Pancreatitis concerns
In 2013, a group at Johns Hopkins reported an apparently statistically significant association between hospitalization for acute pancreatitis and prior treatment with GLP-1 derivatives such as exenatide and sitagliptin In response, the United States FDA and the European Medicines Agency conducted a review of all available data regarding the possible connection between incretin mimetics and pancreatitis or pancreatic cancer. In a joint 2014 letter to the New England Journal of Medicine, the agencies concluded that "A pooled analysis of data from 14,611 patients with type 2 diabetes from 25 clinical trials in the sitagliptin database provided no compelling evidence of an increased risk of pancreatitis or pancreatic cancer" and "Both agencies agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data. The FDA and the EMA have not reached a final conclusion at this time regarding such a causal relationship. Although the totality of the data that have been reviewed provides reassurance, pancreatitis will continue to be considered a risk associated with these drugs until more data are available; both agencies continue to investigate this safety signal."
On Feb, 14, 2016: 12,158 people reported to have side effects when taking Victoza. Among them, 101 people (0.83%) have Pancreatic Cancer.
Time on Victoza when people have Pancreatic cancer :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Pancreatic cancer | 21.92% | 39.73% | 27.40% | 9.59% | 1.37% | 0.00% | 0.00% |
*************************************************************************
On Jan, 10, 2017 22,371 people reported to have side effects when taking Victoza.
Among them, 13 people (0.06%) have Hallucination
On Feb, 4, 2016: 12,156 people reported to have side effects when taking Victoza. Among them, 67 people (0.55%) have Death.
Time on Victoza when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 50.00% | 25.00% | 8.33% | 16.67% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Victoza :
| Female | Male | |
| Death | 35.14% | 64.86% |
Age of people who have Death when taking Victoza :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 0.00% | 13.64% | 1.52% | 27.27% | 57.58% |